Sodium valproate is associated with birth defects. Therefore, it is contraindicated to women of childbearing potential, unless the patient is on the pregnancy prevention programme (PPP). Sodium valproate is prescribed mainly for epilepsy and bipolar disease but can also be used for migraines.
For women of childbearing potential, where there is no other alternative medication due to efficacy and or side effects, sodium valproate can be prescribed but the woman must be on the pregnancy prevention programme, which ensures the woman is on a user independent highly effective contraception e.g., copper IUD. A risk acknowledgement form must be signed by the patient stating the risks associated with taking sodium valproate are understood. The medication must be supplied in the original box containing the warning of potential harm to child bearing women along with a card and patient pack. The risk assessment should be updated annually.
Despite this guidance, it has been found that women are still being prescribed sodium valproate whilst pregnant.
For more information, please see this article below or get in touch with pharmacist at speeds.